The multivariate survival analysis suggested that the high expression of CXCL17 served as an independent biomarker of favorable prognosis in GC patients (p = 0.027; HR = 0.484, 95%CI = 0.255–0.919) (Figure 4c). This evidence concerns the gene CXCL17 and gastric cancer.